PROWESS, ENHANCE and ADDRESS. Clinical implications for the treatment with drotrecogin alfa (activated);PROWESS, ENHANCE und ADDRESS. Klinische konsequenzen für die behandlung mit drotrecogin alfa (aktiviert)

Anaesthesist

Volumn 55, Issue SUPPL. 2, 2006, Pages

  Cobas Meyer, M ^a,b,f   Langenfeld, H ^c   Rossaint, R ^d   Sablotzki, A ^e  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b Universitätsklinikum ^*

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e Klinikum St Georg   (Germany)

^f NONE   (Germany)

Author keywords

Drotrecogin alfa (activated); Organ failure; Sepsis

Indexed keywords

DROTRECOGIN;

APACHE; CLINICAL TRIAL; DEATH; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; MORTALITY; MULTIPLE ORGAN FAILURE; REVIEW; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33748928787     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Abraham E, Laterre P-F, Garg R et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332-1341
2. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709
3. Bernard GR, Macias WL, Joyce DE et al. (2003) Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 7(2): 155-163
4. Committee for Medicinal Products for Human Use (2005) Post-authorisation summary of opinion for Xigris.http://www.emea.eu.int/pdfs/human/opinion/ 13844705en.pdf. Cited15 March 2006
5. Dellinger RP (2006) Recombinant activated protein C: decisions for administration. Crit Care Med 34(2): 530-531
6. Dellinger RP (2006) Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis. Crit Care 10(1): 114-115
7. Dellinger RP, Carlet JM, Masur H et al.; Surviving Sepsis Campaign Management Guidelines Committee (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32(3): 858-873
8. Dhainaut JF, Laterre PF, Janes JM et al.; Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29(6): 894-903
9. European Agency for the Evaluation of Medicinal Products (EMEA) (2002) European Public Assessment Report (EPAR) Xigris. European Agency for the Evaluation of Medicinal Products.http://www.eudra.org/humandocs/Humans/EPAR/ Xigris/xigris.htm. Cited 15 March 2006
10. Kalil AC, Coyle SM, Um JY et al. (2004) Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21(3): 222-229
11. Laterre PF, Wittebole X (2003) Clinical review: drotrecogin alfa (activated) as adjunctive therapy for severe sepsis - Practical aspects at the bedside and patient identification. Crit Care 7(6): 445-450
12. Levy MM, Macias WL, Vincent JL et al. (2005) Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 33(10): 2412-2414
13. Macias WL, Yan SB, Williams MD et al. (2005) New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 9 [Suppl 4]: S38-45
14. Nick JA, Coldren CD, Geraci MW et al. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104(13): 3878-3885
15. Rivers E, Nguyen B, Havstad S et al.; Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19): 1368-1377
16. Vincent JL, Angus DC, Artigas A et al.; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31(3): 834-840
17. Vincent JL, Bernard GR, Beale R et al.; ENHANCE Study Group (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33(10): 2266-2277